Skip to content

Arrowhead Research ARWR Contract Liabilities

Contract Liabilities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$75.75M-46.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$11.78M
Moderna logo
ModernaMRNA
$154M+166%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
Charles River Laboratories logo
Charles River LaboratoriesCRL

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's contract liabilities?
Arrowhead Research (ARWR) reported contract liabilities of $48.62M in Q1 2026.
What is the long-term trend for Arrowhead Research's contract liabilities?
Over 3 years (2021 to 2025), Arrowhead Research's contract liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $131.5M to $0.